Outcomes Associated With COVID-19 Hospitalization in Heart Transplantation Patients

Area of Science:

• Cardiology
• Infectious Diseases
• Immunology

Background:

• Heart transplantation (HT) recipients are often chronically immunosuppressed, potentially increasing their risk of severe COVID-19.
• Understanding COVID-19 outcomes in HT patients is crucial for managing post-transplant care.

Purpose of the Study:

• To compare COVID-19 outcomes in heart transplant recipients versus non-transplant controls.
• To analyze the impact of time since transplantation on COVID-19 severity in HT patients.

Main Methods:

• Retrospective cohort study of adult HT patients hospitalized with COVID-19 (March 2020-March 2021).
• Matched 24 HT cases with 96 non-HT controls based on baseline characteristics.
• Assessed all-cause mortality, mechanical ventilation, ICU admission, vasopressor need, dialysis, pneumonia, and 90-day readmission.

Main Results:

• No significant differences were observed in primary (all-cause mortality) or secondary outcomes between HT recipients and controls.
• Subgroup analysis showed no significant difference in mortality or 30-day readmission based on time from transplantation (within 1 year vs. >1 year).
• Immunosuppressant management (continuation, dose reduction, or discontinuation) did not significantly affect HT patient mortality.

Conclusions:

• Heart transplant recipients with COVID-19 may not have worse outcomes than non-transplant patients, even within the first year post-transplant.
• Further research with larger, multicenter datasets is needed to investigate variants, long COVID, and varying immunosuppression strategies.